Margaux Hall and David McIntosh Present at Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities

Margaux Hall, health care partner and leader of the firm’s drug pricing and price reporting group, and IP transactions and life sciences licensing partner David McIntosh will present at the 2^nd Annual Forum on IP, Funding and Tech Strategies for Novel Therapeutic Modalities in Boston on March 21.

Margaux will host a presentation entitled “Valuing Innovation: Market Dynamics and the Commercial Viability of Novel Therapeutics.” Margaux will discuss topics including key market drivers, analyzing trends influencing investment and adoption, and projecting the financial sustainability of cutting-edge therapies. She will also address anticipating market fluctuations and strategically positioning novel therapeutics for enduring success in a competitive health care market.

David will present on the panel entitled “The AI Advantage in Novel Therapeutics: Understanding How Artificial Intelligence is Revolutionizing Drug Discovery and Development.” The panel will explore topics including the ways AI algorithms and machine learning are accelerating the discovery of new drugs, optimizing development pathways and predicting patient responses; evaluating AI’s impact on transactions, M&A and investment trends; navigating unique deal terms in AI transactions including data ownership, usage rights and financial implications; leveraging AI to design more efficient clinical trials, enhance patient selection and monitor real-time data; and address ethical, legal and practical challenges of using large datasets in AI.

The event is focused on the complex interplay of evolving market trends, dynamic regulatory frameworks and critical intellectual property strategies in the life sciences areas of RNA, gene editing and regenerative medicine, and AI’s transformative role in drug discovery, and the intricacies of navigating the legal and regulatory landscapes.